Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13111275 | 0.87 | ESR1 (0.31) | — | |
| SCHEMBL14878262 | 0.87 | ESR1 (0.31) | — | |
| SCHEMBL15381142 | 0.82 | — | — | |
| SCHEMBL19204391 | 0.78 | CYP3A4 (0.35) | CYP3A4TDP1 | |
| SCHEMBL15684599 | 0.78 | CYP3A4 (0.35) | CYP3A4TDP1 | |
| SCHEMBL17470176 | 0.78 | CYP3A4 (0.35) | CYP3A4TDP1 | |
| SCHEMBL15095794 | 0.78 | CYP3A4 (0.35) | CYP3A4TDP1 | |
| SCHEMBL15344715 | 0.77 | — | — | |
| SCHEMBL16350577 | 0.77 | CYP3A4 (0.31) | CYP3A4TDP1 | |
| SCHEMBL15344675 | 0.76 | ROCK2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061973-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-8946481-B2 | Process for preparing biaryl substituted 4-amino butyric acid or derivatives thereof and their use in the production of NEP inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140243546-A1 | Processes | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-7799818-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7598285-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090043106-A1 | Manufacture of Lactones | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | CYP3A4 78/4885TDP1 2914/4885 |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | CYP3A4 89/4885TDP1 3965/4885 |
| US-20090043106-A1 | Manufacture of Lactones | CA1, CA12, COASY | CYP3A4 257/4885TDP1 4853/4885 |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | GOT2, GOT1, IAPP | CYP3A4 231/4885TDP1 1581/4885 |
| US-20140243546-A1 | Processes | MME, NAT1, AGTR1 | CYP3A4 528/4885TDP1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.